Adaptive Responses to PARP Inhibition Predict Response to Olaparib and Durvalumab in the AMTEC Trial.

Mitri ZI, Stommel JM, Creason AL, Ozmen TY, Rames MJ, Ozmen F, Bottomly D, Jeong B, Lim JY, Sivagnanam S, Betre K, Lee J, Labrie M, Coussens LM, Corless CL, McWeeney SK, Mills GB

Open source

DOI: 10.21203/rs.3.rs-11196611/v1
Published: 2026 Oct 23
Container: Research square
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.21203/rs.3.rs-11196611/v1,
  title = {Adaptive Responses to PARP Inhibition Predict Response to Olaparib and Durvalumab in the AMTEC Trial.},
  author = {Mitri ZI and Stommel JM and Creason AL and Ozmen TY and Rames MJ and Ozmen F and Bottomly D and Jeong B and Lim JY and Sivagnanam S and Betre K and Lee J and Labrie M and Coussens LM and Corless CL and McWeeney SK and Mills GB},
  year = {2026},
  journal = {Research square},
  doi = {10.21203/rs.3.rs-11196611/v1},
  url = {https://doi.org/10.21203/rs.3.rs-11196611/v1}
}

RIS

TY  - JOUR
TI  - Adaptive Responses to PARP Inhibition Predict Response to Olaparib and Durvalumab in the AMTEC Trial.
AU  - Mitri ZI
AU  - Stommel JM
AU  - Creason AL
AU  - Ozmen TY
AU  - Rames MJ
AU  - Ozmen F
AU  - Bottomly D
AU  - Jeong B
AU  - Lim JY
AU  - Sivagnanam S
AU  - Betre K
AU  - Lee J
AU  - Labrie M
AU  - Coussens LM
AU  - Corless CL
AU  - McWeeney SK
AU  - Mills GB
PY  - 2026
JO  - Research square
DO  - 10.21203/rs.3.rs-11196611/v1
UR  - https://doi.org/10.21203/rs.3.rs-11196611/v1
ER  -

APA

ZI, M., JM, S., AL, C., TY, O., MJ, R., F, O., D, B., B, J., JY, L., S, S., K, B., J, L., M, L., LM, C., CL, C., SK, M., & GB, M. (2026). Adaptive Responses to PARP Inhibition Predict Response to Olaparib and Durvalumab in the AMTEC Trial.. Research square. https://doi.org/10.21203/rs.3.rs-11196611/v1

Source records

pubmed · retrieved 2026-11-10T14:28:55.495Z